Receptor News and Research

RSS

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Vitamin D receptor gene variant protects against male LUTS

An international research effort aimed at identifying the genetic basis of lower urinary tract symptoms has identified five candidate genes, one of which – encoding the vitamin D receptor – is consistently protective against these symptoms in men.

17 Mar 2014

Researchers develop therapy to attack cervical cancer tumors

One of the most promising technologies for the treatment of various cancers is nanotechnology, creating drugs that directly attack the cancer cells without damaging other tissues' development.

17 Mar 2014

Findings reveal that miR-34 genes are bona fide tumor suppressors

Cornell University researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.

17 Mar 2014

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant.

17 Mar 2014

Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize for research on immune system

Michael Reth has won the Paul Ehrlich and Ludwig Darmstaedter Prize, awarded by the Paul Ehrlich Foundation, for his research on the immune system. For the first time since 1996, the prize goes to a scientist working in Germany.

17 Mar 2014

Monash University research offers new hope to people with heart attacks

Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.

11 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

New theory regarding cause and development of endometriosis

Changes to two previously unstudied genes are the centerpiece of a new theory regarding the cause and development of endometriosis, a chronic and painful disease affecting 1 in 10 women.

10 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

Receptor News and Research

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

Trovagene reports net loss of $1 million for fourth quarter 2013

Vitamin D receptor gene variant protects against male LUTS

Researchers develop therapy to attack cervical cancer tumors

Findings reveal that miR-34 genes are bona fide tumor suppressors

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize for research on immune system

Monash University research offers new hope to people with heart attacks

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

New theory regarding cause and development of endometriosis

Erlotinib has promising potential to improve treatment for cervical cancer

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Scientists identify important step toward shutting down growth of prostate cancer cells

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

Study to understand how bisphenol-A may promote breast cancer growth

Inflammation and stress combine in bipolar and schizophrenia subtypes

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Monell Center announces advocacy program to identify biological causes of smell loss

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News